title: Osteoporosis in patients taking selective serotonin reuptake inhibitors: a focus on fracture outcome.
abstract: Depression is one of the most important mental health problems and a leading cause of disability. Selective serotonin reuptake inhibitors (SSRIs) are considered as first-line therapy for the treatment of depressive symptoms among older adults because of their presumed favorable adverse effect profile. However, they could have deleterious effects on the bone. Evidence from longitudinal, cross-sectional, and prospective cohort studies suggests that the use of antidepressants at therapeutic doses is associated with decreased bone mineral density and increased fracture risk. The association between SSRIs use and fracture risk could potentially differ depending on dose, exposure duration, time of exposure, age, or sex. However, the risk of fracture declined rapidly after discontinuation of use of SSRIs. The evidence now seems sufficient to consider adding SSRIs to the list of medications that contribute to osteoporosis. In practice, assessment of risk factor for osteoporosis or fractures could be made taking into account age, gender, duration, and severity of depression, length of SSRI treatments, and other concurrent risk factors.
authors.affiliation: Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Bât B23, 4000, Liège, Belgium, olivier.bruyere@ulg.ac.be.
authors.forename: Olivier
authors.initials: O
authors.lastname: Bruyère
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Reginster
mesh_terms: D000818:Animals; D003863:Depression / Q000150:complications / Q000188:drug therapy; D050723:Fractures, Bone / Q000453:epidemiology / Q000628:therapy*; D006801:Humans; D010024:Osteoporosis / Q000139:chemically induced* / Q000453:epidemiology*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D017367:Selective Serotonin Reuptake Inhibitors
references.citation: Bone. 2010 Jan;46(1):13-7
references.pmid: 19664737
references.citation: Osteoporos Int. 2013 Jan;24(1):121-37
references.pmid: 22638709
references.citation: J Bone Miner Res. 2013 Apr;28(4):753-63
references.pmid: 23165455
references.citation: Maturitas. 1999 Oct 24;33(2):133-7
references.pmid: 10597877
references.citation: Int Clin Psychopharmacol. 2008 Mar;23(2):84-7
references.pmid: 18301122
references.citation: Epidemiol Perspect Innov. 2004 Oct 04;1(1):3
references.pmid: 15507128
references.citation: Arch Public Health. 2013 Feb 04;71(1):2
references.pmid: 23379576
references.citation: Bone. 2012 Oct;51(4):674-9
references.pmid: 22889722
references.citation: J Am Board Fam Med. 2011 Jan-Feb;24(1):33-8
references.pmid: 21209342
references.citation: Bone. 2012 Sep;51(3):606-13
references.pmid: 22659406
references.citation: BMJ. 2009 Oct 15;339:b3999
references.pmid: 19833707
references.citation: Clin Pharmacol Ther. 2011 Jun;89(6):880-7
references.pmid: 21508938
references.citation: Arch Intern Med. 2007 Jun 25;167(12):1246-51
references.pmid: 17592097
references.citation: Br J Gen Pract. 2011 Sep;61(590):e565-72
references.pmid: 22152736
references.citation: Epidemiol Psichiatr Soc. 2006 Jan-Mar;15(1):4-10
references.pmid: 16584097
references.citation: J Cell Biol. 2010 Oct 4;191(1):7-13
references.pmid: 20921133
references.citation: Osteoporos Int. 2013 Feb;24(2):671-80
references.pmid: 22669469
references.citation: Endocrine. 2012 Aug;42(1):39-51
references.pmid: 22618377
references.citation: Osteoporos Int. 2009 Oct;20(10):1705-13
references.pmid: 19238308
references.citation: Arch Intern Med. 2007 Jun 25;167(12):1240-5
references.pmid: 17592096
references.citation: Osteoporos Int. 2014 May;25(5):1473-81
references.pmid: 24566587
references.citation: Acta Psychiatr Scand Suppl. 2004;(420):21-7
references.pmid: 15128384
references.citation: J Musculoskelet Neuronal Interact. 2008 Apr-Jun;8(2):133-45
references.pmid: 18622082
references.citation: Ann Pharmacother. 2012 Jul-Aug;46(7-8):917-28
references.pmid: 22811347
references.citation: Osteoporos Int. 2014 Mar;25(3):847-55
references.pmid: 24448776
references.citation: Eur Neuropsychopharmacol. 2009 Oct;19(10):683-92
references.pmid: 19541458
references.citation: BMJ. 1999 May 1;318(7192):1188-91
references.pmid: 10221948
references.citation: Age Ageing. 2013 Jul;42(4):514-20
references.pmid: 23438446
references.citation: Ann Pharmacother. 2009 Jan;43(1):98-103
references.pmid: 19116378
references.citation: J Bone Miner Res. 2012 May;27(5):1186-95
references.pmid: 22258738
references.citation: Endocrine. 2012 Feb;41(1):58-69
references.pmid: 22180055